Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.